Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$25.77
-0.2%
$24.54
$15.73
▼
$30.00
$13.33B0.687.51 million shs4.49 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,444.05
+0.0%
$1,242.25
$850.51
▼
$1,460.00
$1.36T0.42.99 million shs2.08 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
0.00%+0.14%+1.95%-0.46%+39.63%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+5.24%+14.79%+21.92%+40.93%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Baxter International Inc. stock logo
BAX
Baxter International
$25.77
-0.2%
$24.54
$15.73
▼
$30.00
$13.33B0.687.51 million shs4.49 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$1,444.05
+0.0%
$1,242.25
$850.51
▼
$1,460.00
$1.36T0.42.99 million shs2.08 million shs
7 Best Space Stocks to Own in 2026 Cover

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Baxter International Inc. stock logo
BAX
Baxter International
0.00%+0.14%+1.95%-0.46%+39.63%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.00%+5.24%+14.79%+21.92%+40.93%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Baxter International Inc. stock logo
BAX
Baxter International
1.86
Reduce$23.27-9.69% Downside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.83
Moderate Buy$1,416.64-1.90% Downside

Current Analyst Ratings Breakdown

Latest BAX and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/13/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
UpgradeBuy (B) ➝ Buy (B+)
11/12/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy ➝ Hold
11/9/2026
Baxter International Inc. stock logo
BAX
Baxter International
Boost Price TargetUnderweight$20.00 ➝ $23.00
11/9/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,610.00 ➝ $1,700.00
11/2/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetOverweight$1,440.00 ➝ $1,600.00
10/30/2026
Baxter International Inc. stock logo
BAX
Baxter International
UpgradeSell (D-) ➝ Sell (D)
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
DowngradeBuy (B+) ➝ Buy (B)
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,300.00 ➝ $1,550.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Boost Price TargetBuy$1,425.00 ➝ $1,625.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingOutperform$1,650.00
10/30/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Reiterated RatingBuy$1,497.00
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Baxter International Inc. stock logo
BAX
Baxter International
$11.24B1.19$5.68 per share4.54$11.87 per share2.17
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$65.18B20.84$25.15 per share57.42$28.07 per share51.44
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Baxter International Inc. stock logo
BAX
Baxter International
-$957M-$1.41N/A12.703.79-6.23%16.23%5.08%N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$20.64B$30.8146.8728.481.7331.90%86.76%22.03%2/3/2027 (Estimated)

Latest BAX and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/29/2026Q3 2026
Baxter International Inc. stock logo
BAX
Baxter International
$0.5180$0.58+$0.0620$0.57$2.91 billion$2.98 billion
10/29/2026Q3 2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.71$7.48+$1.77$7.22$22.58 billion$24.40 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Baxter International Inc. stock logo
BAX
Baxter International
$0.040.16%-11.54%N/A N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$6.920.48%+15.18%22.46%11 Years

Latest BAX and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/28/2026
Baxter International Inc. stock logo
BAX
Baxter International
quarterly$0.010.17%11/27/202611/27/20261/4/2027
10/26/2026
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
quarterly$1.730.48%11/13/202611/13/202612/10/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Baxter International Inc. stock logo
BAX
Baxter International
1.20
1.79
1.19
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.17
1.39
1.00

Institutional Ownership

CompanyInstitutional Ownership
Baxter International Inc. stock logo
BAX
Baxter International
90.19%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
Baxter International Inc. stock logo
BAX
Baxter International
0.17%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.14%
CompanyEmployeesShares OutstandingFree FloatOptionable
Baxter International Inc. stock logo
BAX
Baxter International
37,500517.35 million516.47 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
50,000940.74 million939.43 millionOptionable

Recent News About These Companies

Top Pharmaceutical Stocks To Keep An Eye On - November 15th
Top Healthcare Stocks To Watch Now - November 15th
Danske Bank A S Sells 71,588 Shares of Eli Lilly and Company $LLY
What Is The Market Seeing In Eli Lilly Stock?
What Eli Lilly Doubters Overlooked
Pharmaceutical Stocks Worth Watching - November 13th
Best Healthcare Stocks To Follow Today - November 13th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Baxter International stock logo

Baxter International NYSE:BAX

$25.77 -0.04 (-0.15%)
Closing price 11/13/2026 03:59 PM Eastern
Extended Trading
$25.51 -0.26 (-1.01%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.

Eli Lilly and Company stock logo

Eli Lilly and Company NYSE:LLY

$1,444.05 +0.55 (+0.04%)
Closing price 11/13/2026 03:59 PM Eastern
Extended Trading
$1,438.50 -5.55 (-0.38%)
As of 11/13/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.